Concepedia

Tumor necrosis factor α release is a major biological event associated with rituximab treatment

Jacques Bienvenu, Roland Chvetzoff, Gilles Salles, Cécile Balter, Hervé Tilly, Raoul Herbrecht, Pierre Morel, P Lederlin, Philippe Solal‐Céligny, B. Audhuy,

The Hematology Journal · 2001 · 98 citations · 13 references

DOI

Concepts

References

13

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

, , +17

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · Nature Medicine · 2000 · 2.7K citations

, , +15

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

, , +14

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

B. Coiffier, Corinne Haïoun, Nicolas Ketterer et al. · PubMed · 1998 · 898 citations

, , +15

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

DG Maloney, TM Liles, DK Czerwinski et al. · Blood · 1994 · 753 citations

, , +17